Literature DB >> 7536475

The impact of interferon versus busulfan therapy on the reticulin stain-measured fibrosis in CML--a comparative morphometric study on sequential trephine biopsies.

J Thiele1, H M Kvasnicka, N Niederle, T K Zirbes, M Schmidt, J Dammasch, B R Meuter, L D Leder, O Kloke, V Diehl.   

Abstract

To evaluate treatment-related changes of the reticulin stain-measured fibrosis in Ph(1+)-CML, a clinicopathological study was performed on sequential trephine biopsies of the bone marrow following either interferon (IFN) or busulfan (BU) monotherapy. Using the monoclonal antibody CD61 for the identification of megakaryopoiesis and Gomori's silver impregnation method, number of megakaryocytes and density of argyrophilic (reticulin and collagen) fibers were determined by morphometry. We studied specimens from 26 patients with IFN-alpha 2b (including nine patients with additional IFN gamma) therapy and from 23 patients who had received BU. In both groups, repeated bone marrow biopsies (total 125) revealed a significant increase in the fiber content, as well as in the number of megakaryocytes during treatment. To assess the dynamics of myelofibrosis more precisely, computation of differences in the degree of fiber density between the first and last examination was carried out. Regarding the considerable variations in the biopsy intervals, a so-called myelofibrosis progression index (MPI) was calculated. Following this rationale, we were able to demonstrate that, in comparison to the BU-group, speed of progression of bone marrow fibrosis was significantly increased in CML patients treated with IFN. Preliminary statistical analysis indicated a relationship between myelofibrosis on admission, which was always associated with increased growth of megakaryocytes, and the MPI with survival. Even when these parameters were regarded, prognosis was significantly more favorable in the IFN-treated patients. The failure of IFN and BU to inhibit the evolution of myelofibrosis may be related to several conversely acting pathomechanisms. Among others, the inability of both therapeutic agents to reduce the number of megakaryocytes more effectively should be taken into consideration.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7536475     DOI: 10.1007/bf01682031

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  52 in total

1.  Reticulin fibre content of bone marrow infiltrates of malignant non-Hodgkin's lymphomas (B-cell type, low malignancy)--a morphometric evaluation before and after therapy.

Authors:  J Thiele; J Langohr; M Skorupka; R Fischer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

2.  The immunohistological detection of platelets, megakaryocytes and thrombi in routinely processed specimens.

Authors:  K C Gatter; J L Cordell; H Turley; A Heryet; N Kieffer; D J Anstee; D Y Mason
Journal:  Histopathology       Date:  1988-09       Impact factor: 5.087

3.  Histological features of prognostic significance in CML--an immunohistochemical and morphometric study (multivariate regression analysis) on trephine biopsies of the bone marrow.

Authors:  J Thiele; H M Kvasnicka; B R Titius; U Parpert; R Nebel; R Zankovich; D Dienemann; H Stein; V Diehl; R Fischer
Journal:  Ann Hematol       Date:  1993-06       Impact factor: 3.673

4.  Myelofibrosis in chronic myeloproliferative disorders. Incidence among subtypes according to the Hannover Classification.

Authors:  T Buhr; A Georgii; H Choritz
Journal:  Pathol Res Pract       Date:  1993-03       Impact factor: 3.250

5.  Effect of alpha-interferon therapy on bone marrow fibrosis in hairy cell leukemia.

Authors:  M Laughlin; A Islam; M Barcos; P Meade; H Ozer; M Gavigan; E Henderson; T Han
Journal:  Blood       Date:  1988-09       Impact factor: 22.113

6.  Long-term treatment of chronic myelogenous leukemia with different interferons: results from three studies.

Authors:  N Niederle; O Kloke; U B Wandl; R Becher; T Moritz; B Opalka
Journal:  Leuk Lymphoma       Date:  1993-01

7.  Myelofibrosis in chronic granulocytic leukaemia: clinicopathologic correlations and prognostic significance.

Authors:  M Lazzarino; E Morra; A Castello; D Inverardi; A Coci; G Pagnucco; U Magrini; G Zei; C Bernasconi
Journal:  Br J Haematol       Date:  1986-10       Impact factor: 6.998

8.  Chemotherapy resolves symptoms and reverses marrow fibrosis in myelofibrosis.

Authors:  A Manoharan; W R Pitney
Journal:  Scand J Haematol       Date:  1984-11

9.  Toxicological review of busulfan (Myleran).

Authors:  J B Bishop; J S Wassom
Journal:  Mutat Res       Date:  1986-07       Impact factor: 2.433

10.  Morphometric assessment of bone marrow fiber content in acute nonlymphatic leukemia at presentation.

Authors:  I Fohlmeister; H Klein; J Thiele; S Wienhold; R Fischer
Journal:  Anal Quant Cytol Histol       Date:  1988-04       Impact factor: 0.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.